Cost Effectiveness of Leukotriene Receptor Antagonists versus Inhaled Corticosteroids for Initial Asthma Controller Therapy A Pragmatic Trial

Research output: Contribution to journalArticle

Authors

  • ECF Wilson
  • EJ Sims
  • SD Musgrave
  • L Shepstone
  • A Blyth
  • J Murdoch
  • HM Mugford
  • EF Juniper
  • S Wolfe
  • D Freeman
  • RFT Gilbert
  • I Harvey
  • EV Hillyer
  • D Price

Abstract

Background: Information is lacking on the relative effectiveness and cost effectiveness in a primary-care setting of leukotriene receptor antagonists (LTRAs) as an alternative to inhaled corticosteroids (ICS) for initial asthma controller therapy. Objective: To compare the cost effectiveness of LTRAs versus ICS for patients initiating asthma controller therapy. Methods: An economic evaluation was conducted alongside a 2-year, pragmatic, randomized controlled trial set in 53 primary-care practices in the UK. Patients aged 12-80 years with asthma and symptoms requiring regular anti-inflammatory therapy (n = 326) were randomly assigned to LTRAs (n = 162) or ICS (n = 164). The main outcome measures were the incremental costs per point improvement in the Mini Asthma Quality of Life Questionnaire, per point improvement in the Asthma Control Questionnaire and per QALY gained from the UK NHS and societal perspectives. Results: Over 2 years, resource use was similar between the two treatment groups, but the cost to society per patient was significantly higher for the LTRA group, at 711 pound versus 433 pound for the ICS group (adjusted difference 204; pound 95% CI 74, 308) [year 2005 values]. Cost differences were driven primarily by differences in prescription drug costs, particularly study drug costs. There was a nonsignificant (imputed, adjusted) difference between treatment groups, favouring ICS, in QALYs gained at 2 years of 0.073 (95% CI -0.143, 0.010). Therapy with LTRAs was, on average, a dominated strategy, and, at a threshold for willingness to pay of 30000 per QALY gained, the probability of LTRAs being cost effective compared with ICS was approximately 3% from both societal and NHS perspectives. Conclusions: There is a very low probability of LTRAs being cost effective in the UK, at 2005 values, compared with ICS for initial asthma controller therapy. Trial registration: UK National Research Register N0547145240; Controlled Clinical Trials ISRCTN99132811.

Details

Original languageEnglish
Pages (from-to)585-595
Number of pages11
JournalPharmacoEconomics
Volume28
Issue number7
Publication statusPublished - 1 Jan 2010